NZ725492A - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders - Google Patents

2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Info

Publication number
NZ725492A
NZ725492A NZ725492A NZ72549215A NZ725492A NZ 725492 A NZ725492 A NZ 725492A NZ 725492 A NZ725492 A NZ 725492A NZ 72549215 A NZ72549215 A NZ 72549215A NZ 725492 A NZ725492 A NZ 725492A
Authority
NZ
New Zealand
Prior art keywords
treatment
disease
nervous system
central nervous
system disorders
Prior art date
Application number
NZ725492A
Other languages
English (en)
Inventor
Collazo Ana María García
David John Augustus Eckland
Lalanza Maria Pilar Pizcueta
Pedemonte Marc Martinell
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of NZ725492A publication Critical patent/NZ725492A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ725492A 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders NZ725492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382130 2014-04-02
PCT/EP2015/057224 WO2015150476A1 (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
NZ725492A true NZ725492A (en) 2023-06-30

Family

ID=50513194

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ725492A NZ725492A (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Country Status (24)

Country Link
US (3) US9782395B2 (Direct)
EP (2) EP3125888B1 (Direct)
JP (2) JP6745726B2 (Direct)
KR (1) KR102418167B1 (Direct)
CN (1) CN106470991B (Direct)
AU (1) AU2015239112C1 (Direct)
CA (1) CA2943373C (Direct)
CL (1) CL2016002508A1 (Direct)
CY (2) CY1120454T1 (Direct)
DK (2) DK3388064T3 (Direct)
EA (2) EA035866B1 (Direct)
ES (2) ES2678046T3 (Direct)
HR (2) HRP20180983T1 (Direct)
HU (2) HUE039555T2 (Direct)
IL (1) IL248037B (Direct)
LT (2) LT3125888T (Direct)
MX (1) MX373234B (Direct)
NZ (1) NZ725492A (Direct)
PL (2) PL3388064T3 (Direct)
PT (2) PT3125888T (Direct)
SG (1) SG11201608218QA (Direct)
SI (2) SI3125888T1 (Direct)
WO (1) WO2015150476A1 (Direct)
ZA (1) ZA201607286B (Direct)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
SG11201608218QA (en) * 2014-04-02 2016-10-28 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
AU2017370003B2 (en) * 2016-12-01 2023-04-13 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
ES2926580T3 (es) * 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
CN112823004A (zh) * 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途
CA3102407A1 (en) * 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
LT3801515T (lt) * 2018-06-06 2025-06-10 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dionas ir jo druskos, skirti mitochondrinių ligų gydymui
US20230172921A1 (en) 2020-04-30 2023-06-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
WO1992018501A1 (en) * 1991-04-11 1992-10-29 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
WO1993022445A1 (en) * 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20050107450A1 (en) 2001-12-21 2005-05-19 Brown Kathleen K. Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
WO2005016339A1 (en) * 2003-07-24 2005-02-24 Case Western Reserve University Methods for the treatment of parkinson's disease
CA2646207C (en) * 2006-03-16 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
CA2783556C (en) * 2009-12-15 2017-12-12 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) * 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
JP6800013B2 (ja) * 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
SG11201608218QA (en) * 2014-04-02 2016-10-28 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Also Published As

Publication number Publication date
ZA201607286B (en) 2021-07-28
HUE055351T2 (hu) 2022-05-28
US20190255032A1 (en) 2019-08-22
EP3388064A1 (en) 2018-10-17
LT3388064T (lt) 2021-05-25
US10179126B2 (en) 2019-01-15
EP3125888B1 (en) 2018-05-23
SI3388064T1 (sl) 2021-08-31
AU2015239112C1 (en) 2020-08-20
PL3388064T3 (pl) 2021-07-19
HRP20210518T1 (hr) 2021-05-14
SI3125888T1 (en) 2018-08-31
JP6745726B2 (ja) 2020-08-26
EA202091120A3 (ru) 2020-12-30
CL2016002508A1 (es) 2017-04-21
AU2015239112B2 (en) 2020-05-07
EA201691997A1 (ru) 2017-02-28
EA035866B1 (ru) 2020-08-21
LT3125888T (lt) 2018-07-10
CA2943373A1 (en) 2015-10-08
CN106470991A (zh) 2017-03-01
CN106470991B (zh) 2020-07-31
CA2943373C (en) 2023-01-10
ES2678046T3 (es) 2018-08-08
EP3388064B1 (en) 2021-03-10
CY1124088T1 (el) 2022-05-27
PT3388064T (pt) 2021-05-14
IL248037B (en) 2020-09-30
HUE039555T2 (hu) 2019-01-28
SG11201608218QA (en) 2016-10-28
HRP20180983T1 (hr) 2018-08-10
EP3125888A1 (en) 2017-02-08
AU2015239112A1 (en) 2016-11-10
US9782395B2 (en) 2017-10-10
CY1120454T1 (el) 2019-07-10
KR102418167B1 (ko) 2022-07-08
PT3125888T (pt) 2018-07-20
ES2872335T3 (es) 2021-11-02
DK3125888T3 (en) 2018-06-25
PL3125888T3 (pl) 2018-09-28
JP2020117539A (ja) 2020-08-06
DK3388064T3 (da) 2021-04-19
EA202091120A2 (ru) 2020-08-31
KR20160145639A (ko) 2016-12-20
US20180133202A1 (en) 2018-05-17
US20160235729A1 (en) 2016-08-18
MX373234B (es) 2020-05-08
MX2016012687A (es) 2017-04-27
WO2015150476A1 (en) 2015-10-08
BR112016022974A2 (pt) 2017-12-26
JP2017511339A (ja) 2017-04-20
IL248037A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
IL258862B (en) N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases
FR24C1034I2 (fr) Composés aryle, hétéroaryle et hétérocycliques pour le traitement de troubles induits par un complément
PT3985002T (pt) Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
IL246875A0 (en) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12017500920B1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
IL263188B (en) Treatment for Parkinson's disease
ZA202103106B (en) Heterocyclic compounds for the treatment of epilepsy
PT3373931T (pt) Compostos heterocíclicos para o tratamento de doenças
NZ630803A (en) Optically active pde10 inhibitor
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
HUE045851T2 (hu) Eljárás 2-(2,5-dimetil-1H-pirrol-1-il)-1,3-propándiol és helyettesített származékainak elõállítására
MX2020013537A (es) Compuestos de tiazolidinona y su uso en el tratamiento de trastornos psiquiatricos o neurologicos y de la inflamacion, en particular de la neuroinflamacion.
IL249428A0 (en) A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
HK40053333A (en) Methods for treating parkinson's disease by administering resiniferatoxin
ZA201807944B (en) Treatment for parkinson's disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2025 BY THOMSON REUTERS

Effective date: 20240305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2026 BY THOMSON REUTERS

Effective date: 20250307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2027 BY THOMSON REUTERS

Effective date: 20260306